A World Without Infectious Disease
Bolyn Hubby, Ph.D.
Chief Corporate Affairs Officer
Bolyn Hubby, Ph.D., has served as our Chief Corporate Affairs Officer since August 2020. In this role, she is leading our Public Private Partnerships (P3), Government Affairs, Corporate Communications, and Patient Advocacy efforts. Prior to this role, she served as our Senior Vice President of Research and P3 since June 2019 and served in other management roles at Vir since February 2018. From January 2017 to January 2018, Dr. Hubby was the Chief Scientific Officer at Agenovir Corporation, a gene editing company we acquired in May 2018. Prior to Agenovir, Dr. Hubby worked for Synthetic Genomics Inc. from 2013-2017, where she most recently served as Vice President of Vaccines and Antimicrobials. At Synthetic Genomics, Dr. Hubby and her colleagues advanced the company’s core synthetic biology technology for influenza vaccines into the clinic and developed novel RNA and antimicrobial platforms to address the rapid spread of infectious disease and the growing global threat of antibiotic resistance. Prior to Synthetic Genomics, Dr. Hubby served as Executive Director of Vaccines at Liquidia Technologies, Inc. and Head of Discovery Immunology at AlphaVax, Inc. Dr. Hubby received her B.A. in Anthropology from University of Georgia and her Ph.D. in Cell Biology from the University of Georgia, Department of Cellular Biology and Center for Tropical and Emerging Diseases.